NRx Pharmaceuticals CEO to Discuss Neuroplasticity Treatments at BTIG Conference

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) announced that its CEO and Chairman, Prof. Jonathan Javitt, MD, MPH, will join a fireside chat at the upcoming BTIG Virtual Biotechnology Conference on July 29–30, 2025. The session, set for 8:00 a.m. EDT on July 30, will include Prof. Samuel Wilkinson, MD, from Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader. The discussion will center on the role of neuroplasticity in treating central nervous system (CNS) disorders, with a particular focus on the use of ketamine and other neuroplastic and psychedelic drugs for conditions such as depression, suicidality, and PTSD.

NRx Pharmaceuticals is at the forefront of developing therapeutics based on its NMDA platform, targeting CNS disorders including suicidal bipolar depression, chronic pain, and PTSD. The company's investigational Breakthrough Therapy, NRX-101, is under development for suicidal treatment-resistant bipolar depression and chronic pain, with plans to file for Accelerated Approval. Additionally, NRX-101 is being explored as a non-opioid treatment for chronic pain and a potential remedy for complicated UTI. The company has also initiated a New Drug Application for NRX-100 (IV ketamine) for suicidal depression, leveraging data from clinical trials and French health authorities, under a data sharing agreement.

This participation highlights NRx Pharmaceuticals' commitment to advancing treatments for CNS disorders and its leadership in the biopharmaceutical industry. The fireside chat represents a significant opportunity to discuss the potential of neuroplasticity-based therapies and their implications for patients suffering from severe mental health conditions.